Key clinical point: A combination of atezolizumab plus bevacizumab (ATZ+BV) caused less fatigue in HCC patients as a first-line therapy than when given as a later line therapy, based on the IMbrave150 criteria.
Major finding: Treatment interruption due to fatigue was significantly higher in Child-Pugh B patients who received later treatment compared to Child-Pugh A patients who received early treatment ( P = 0.030). In a multivariate analysis, neutrophil lymphocyte ratios and B-IMbrave150 criteria were independent predictors of objective response to the combination therapy (hazard ratios 4.591 and 4.108, respectively).
Study details: The data come from 94 adults with unresectable HCC treated with ATZ+BV at multiple centers. Of these, 46 Child-Pugh A patients received treatment early (B-IMbrave150-in) and 48 Child-Pugh B patients received the combination as first-line or later line therapy (B-IMbrave150-out).
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Source: Chuma M et al. Hepatol Res. 2021 Nov 10. doi: 10.1111/hepr.13732.